Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023

BUY
$43.24 - $61.04 $259 - $366
6 Added 3.47%
179 $9,000
Q2 2022

Aug 15, 2022

BUY
$35.07 - $59.21 $350 - $592
10 Added 6.13%
173 $8,000
Q4 2021

Feb 14, 2022

BUY
$30.74 - $49.16 $5,010 - $8,013
163 New
163 $8,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.19B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Itau Unibanco Holding S.A. Portfolio

Follow Itau Unibanco Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Itau Unibanco Holding S.A. with notifications on news.